Chemours (NYSE:CC) Price Target Lowered to $21.00 at Mizuho

Chemours (NYSE:CC - Free Report) had its price target trimmed by Mizuho from $22.00 to $21.00 in a report published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the specialty chemicals company's stock.

Several other research firms have also recently weighed in on CC. Morgan Stanley reduced their price objective on Chemours from $30.00 to $25.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 5th. The Goldman Sachs Group dropped their target price on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday. Royal Bank of Canada reissued an "outperform" rating and set a $25.00 target price on shares of Chemours in a report on Thursday, December 12th. Barclays increased their price target on shares of Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Finally, BMO Capital Markets lifted their target price on Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Chemours currently has a consensus rating of "Hold" and an average price target of $24.13.

Chemours Stock Performance

Shares of CC traded up $1.93 during mid-day trading on Tuesday, hitting $18.86. The company's stock had a trading volume of 3,290,020 shares, compared to its average volume of 1,824,955. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The firm has a market capitalization of $2.82 billion, a PE ratio of 37.72 and a beta of 1.83. The stock's 50-day moving average is $19.29 and its two-hundred day moving average is $19.97. Chemours has a one year low of $15.10 and a one year high of $32.48.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.08. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The firm's quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the firm posted $0.64 EPS. As a group, sell-side analysts anticipate that Chemours will post 1.35 EPS for the current year.

Chemours Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.30%. The ex-dividend date of this dividend was Friday, November 15th. Chemours's payout ratio is currently 200.00%.

Insider Transactions at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the transaction, the senior vice president now owns 16,645 shares in the company, valued at approximately $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.47% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Chemours

A number of institutional investors have recently made changes to their positions in CC. KBC Group NV increased its holdings in shares of Chemours by 19.5% during the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock valued at $91,000 after acquiring an additional 728 shares in the last quarter. Blue Trust Inc. raised its holdings in Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 731 shares during the last quarter. GAMMA Investing LLC raised its holdings in Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 765 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Chemours by 2.1% in the second quarter. Arizona State Retirement System now owns 41,657 shares of the specialty chemicals company's stock worth $940,000 after buying an additional 863 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Chemours by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company's stock valued at $349,000 after acquiring an additional 1,175 shares in the last quarter. Institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.